Repaglinide Tablets Combined with Glibenclamide in Gestational Diabetes Mellitus
Objective To analyze the clinical efficacy of repaglinide tablets combined with glibenclamide in the management of patients with gestational diabetes mellitus(GDM).Methods A total of 83 patients with GDM admitted to Neihuang County People's Hospital from April 2021 to April 2023 were selected for the study,and were divided into the single group(n=41,treated with glibenclamide)and the combined group(n=42,treated with Repaglinide tablets combined with glibenclamide).Clinical efficacy,maternal and infant outcomes,indicators of glucose and lipid metabolism[fasting blood glucose(FPG),2 h postprandial glucose(2 hPG),insulin resistance index(HOMA-IR),triglyceride(TG),total cholesterol(TC),low density lipoprotein(LDL-C)],indicators of oxidative stress[superoxide dismutase(SOD),reactive oxygen species(ROS),malondialdehyde(MDA)],and disease-related serologic indicators[Thioredoxin interacting protein(TXNIP),glucododoxin interacting protein(GRP78)]were statistically compared between the 2 groups.Results The total effective rate of the combined group(92.86%)was significantly higher than that of the single group(75.61%,P＜0.05);FPG,2 hPG,TG,TC,LDL-C levels and HOMA-IR in the two groups were lower after treatment than those before treatment(both P＜0.05),and were significantly lower in the combined group than those in the single group(P＜0.05 or P＜0.001);the serum SOD levels in the 2 groups were higher after treatment than those before treatment,while ROS and MDA levels were lower after treatment than before treatment(both P＜0.05),and SOD levels in the combined group were higher than those in the single group,while ROS and MDA levels in the combined group were lower than those in the single group(P＜0.05 or P＜0.001);serum TXNIP and GRP78 levels in the 2 groups were lower after treatment than before treatment(P＜0.05),and serum TXNIP and GRP78 levels in the combined group were lower than those in the single group(P＜0.05 or P＜0.001);the incidence of cesarean section,premature rupture of membranes,fetal distress,preterm delivery and neonatal hypoglycemia were significantly lower in the combined group than in the single group(P＜0.05).Conclusions Repaglinide combined with glibenclamide can have positive clinical efficacy in the management of patients with GDM,which promotes glycolipid metabolism,inhibits oxidative stress,and improves maternal and infant outcomes.
NETL
NSTL
万方数据
